Technology | Cardiovascular Ultrasound | April 09, 2019

LVivo SAX uses AI to identify abnormalities in heart function to assist in detecting heart attacks

DiA Imaging Analysis Introduces LVivo SAX Ultrasound Analysis Tool

April 9, 2019 — DiA Imaging Analysis announced the launch of LVivo SAX, a cardiac analysis tool that helps clinicians quickly and accurately interpret ultrasound images and assess heart functionality among patients suspected of suffering from acute coronary syndrome (ACS).

LVivo SAX uses artificial intelligence (AI) to analyze segmental left ventricle wall motion using the parasternal short axis view. This is a common cardiac view used in point-of-care ultrasound settings, as it provides views of cardiac tissue supplied by all three major coronary vessels and is relatively easy to acquire without manipulating the patient’s posture. The LVivo SAX tool is designed to provide medical clinicians with varying levels of ultrasound analysis or cardiological experience the ability to automatically measure, track and evaluate cardio functions, and to detect abnormalities that reduce variability and increase efficiency.

Emergency room and point-of-care clinicians typically order an electrocardiogram (ECG), a blood test and an ultrasound when a patient presents with ACS symptoms. The ultrasound images, which are vitally important given that ECG and blood tests are not always conclusive, are typically viewed visually. The results are often dependent on the clinician’s level of training and experience. As an integrated part of an ultrasound and information technology (IT) system, LVivo SAX leverages AI to bring objectivity to the process to provide an automated and objective assessment of left ventricular function and segmental function.

“LVivo SAX has the potential to change the way emergency department clinicians manage patients with suspected ACS,” said Chris Moore, M.D., associate professor of emergency medicine at Yale University School of Medicine. Moore will be conducting a post-market clinical study of LVivo SAX within Yale’s emergency room environment.

“Today, the accurate assessment of ultrasound images often depends on the expertise of the interpreter. By delivering reliable and reproducible information related to wall motion abnormalities, LVivo SAX helps doctors arrive at the correct diagnosis and guide the proper care of the patient. We are pleased to take part in DiA’s launch of LVivo SAX and look forward to trialing the tool in our emergency department,” Moore said.

DiA will demonstrate LVivo SAX, as well as its extended LVivo Cardiac Toolbox, at the American Institute of Ultrasound in Medicine (AIUM) 2019 conference, April 6-10 in Orlando, Fla.

For more information: www.dia-analysis.com


Related Content

News | Cardiac Imaging

May 21, 2026 — A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s ...

Time May 22, 2026
arrow
News | X-Ray

May 21, 2026 — RADIN Health and AZmed have announced the expansion of their strategic partnership and enhance radiology ...

Time May 22, 2026
arrow
News | Digital Pathology

May 7, 2026 — Roche has entered into a definitive merger agreement to acquire PathAI, a U.S.-based company in digital ...

Time May 21, 2026
arrow
News | Computed Tomography (CT)

May 12, 2026 – Bracco Imaging S.p.A. has purchased a mobile photon-counting CT scanner from MARS Bioimaging to support ...

Time May 20, 2026
arrow
Feature | Enterprise Imaging | Kyle Hardner

For radiology departments, the imbalance between surging imaging volume and a shortage of trained radiologists is taking ...

Time May 20, 2026
arrow
News | Interventional Radiology

May 12, 2026 — Siemens Healthineers has received clearance from the Food and Drug Administration for six new systems in ...

Time May 12, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

May 11, 2026 – At the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE ...

Time May 11, 2026
arrow
News | Radiopharmaceuticals and Tracers

May 7, 2026 — Bayer has announced positive topline results from the Phase III REVEAL study, an investigator-initiated ...

Time May 08, 2026
arrow
News | Focused Ultrasound Therapy

May 7, 2026 — Openwater, an open-source medical technology company has announced a collaboration with the Sharma Lab, a ...

Time May 07, 2026
arrow
News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
Subscribe Now